EN DE
Watch Kwality Pharmaceuticals Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Kwality Pharmaceuticals Ltd (KPL) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Kwality Pharmaceuticals Ltd stock ₹1,211, price ₹4,195, that is 71.1% below the price, quality 57 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE552U01010

KP Kwality Pharmaceuticals Ltd logo Some data Nov 15, 2026

Kwality Pharmaceuticals Ltd

KPL · BSE

Far too expensive (fair value 71% below the price), but solid company and rising price: meets 2 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Solidly profitable · 14.6% net margin (TTM) 
Low debt 
Wide moat 71/100
Last quarter vs. a year ago: revenue +46%, profit +115%. 
Quality 57/100 
Expensive Growth (revenue 5y +14.8 %/yr in INR) 
Mixed vs. peers (6/12) 
Some data 
Fair value ₹1,211 · Strongly overvalued 
Negative free cash flow 
⚠ Small free float
Watch Kwality Pharmaceuticals Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹4,195 ₹104.50 Fair Value ₹1,211 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range ₹104.50 – ₹4,195 · fair‑value band ₹848.01 – ₹1,575 · the ₹4,195 price screens above the ₹1,211 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Kwality Pharmaceuticals in your weekly email

Every Wednesday you see whether Kwality Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures, buys, sells, and deals finished pharmaceutical formulations in India and internationally.

Show moreShow less

It offers its products in various dosage forms, including liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments/cream, external preparations, ORS, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized and covid products, syrups, daunorubicin, and other various categories, such as Beta Lactam, non-Beta Lactam, hormones, cytotoxic (oncology), and effervescent.

The company also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.

Stock analysis

Kwality Pharmaceuticals Ltd (KPL) currently trades at ₹4,195, while our model-based Fair Value estimate is ₹1,211, 71% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹1,268 per share, and 0 of the 14 models we run sit above the ₹4,195 price.

Bear case: the Asset-Based group reads lowest at ₹139.80, and 14 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹848.01 (bear) to ₹1,575 (bull), the price of ₹4,195 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Kwality Pharmaceuticals Ltd reported revenue of ₹5.0B in FY2025 versus ₹6.3B in FY2021, a compound −5.3%/yr. Reported net income was ₹673M in FY2025, compounding +26.6%/yr from FY2021.

Key figures

Market cap ₹43.5B (≈ $466M) Small · P/E ratio 53.7 · P/S ratio 7.86 · EPS (TTM) ₹78.10 · Net margin 14.6% · Return on equity 22.7% · Return on assets (EBIT) 6.8% (5-year average) · Operating margin 22.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and 381% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −71%, KPL screens richer than that median.

Fair Value models

Bear ₹848.01 Fair Value ₹1,211 Bull ₹1,575
Price ₹4,195 · Downside -71.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (₹68.90 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹319.63 ₹396.48 ₹534.39 76
EPV ₹551.44 ₹617.03 ₹669.68 74
ROIC Compounder ₹572.78 ₹669.07 ₹765.75 72
All 14 models by family
Earnings-Based
Graham-Dodd ₹441.35 ₹1,221 ₹1,604 65
Lynch FV ₹243.98 ₹348.54 ₹453.10 61
PEG = 1.0 ₹243.98 ₹348.54 ₹453.10 57
EPV ₹551.44 ₹617.03 ₹669.68 74
Multiples
P/E Multiple ₹1,071 ₹1,428 ₹1,785 63
P/S Multiple ₹827.53 ₹1,103 ₹1,379 58
P/B Multiple ₹831.21 ₹1,108 ₹1,385 55
EV/EBIT ₹1,085 ₹1,488 ₹1,891 66
EV/EBITDA ₹1,072 ₹1,470 ₹1,869 67
EV/Revenue ₹738.25 ₹1,108 ₹1,478 53
Asset-Based
NCAV (Graham) ₹92.27 ₹139.80 ₹174.76 54
Economic Profit
Residual Income ₹319.63 ₹396.48 ₹534.39 76
ROIC Compounder ₹572.78 ₹669.07 ₹765.75 72
Growth Earnings
Growth-Adj P/E ₹848.01 ₹1,211 ₹1,575 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 68
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 30
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 90
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 100
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−13.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−13.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.39.7% vs 24.3%, picking up
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 20%
2025 sits 3,734% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)

KPL screens overvalued: fair value 71% below the price. Compare with Merck KGaA →

Compare Kwality Pharmaceuticals Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside −71.1% · Bottom 25%
Profitability
Return on equity (12 months) 22.7% · Top 25%
Return on assets 11.4% · Top 25%
Net margin (12 months) 14.6% · Top 25%
Operating margin (12 months) 22.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 45.6% · Top 25%
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 53.7× · Priciest 25%
P/B 13.13× · Priciest 25%
P/S (12 months) 7.86× · Priciest 25%
EV/EBITDA 31.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)91 · sector 26
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.48 $113.53 +36% vs KPL
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.90 ¥52.43 +12% vs KPL
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,872 ₹1,983 +6% vs KPL
Haleon plc HLN $9.05 $8.47 −6% vs KPL
Merck KGaA MRK €149.50 €108.83 −27% vs KPL
Galderma Group GALD CHF 187.55 CHF 112.46 −40% vs KPL
Takeda Pharmaceutical Company TAK $21.64 $11.23 −48% vs KPL
Sandoz Group SDZ CHF 81.50 CHF 40.91 −50% vs KPL
Teva Pharmaceutical Industries Limited TEVA $42.62 $20.74 −51% vs KPL
Divi's Laboratories Limited DIVISLAB ₹11,049 ₹1,567 −86% vs KPL

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kwality Pharmaceuticals Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kwality Pharmaceuticals Ltd Fair Value". https://www.fairvalue-calculator.com/stock/KPL

Frequently asked questions

Is Kwality Pharmaceuticals Ltd (KPL) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ₹1,211 versus a price of ₹4,195, about 71% lower (overvalued).
What is the fair value of KPL?
Our model-based fair value for Kwality Pharmaceuticals Ltd is ₹1,211 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹4,195.
What is the quality score of KPL?
Kwality Pharmaceuticals Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kwality Pharmaceuticals Ltd (KPL)?
Our model-based price target is the fair value of ₹1,211 (as of Nov 15, 2026) from 14 valuation models. Cautious scenario ₹848.01, optimistic scenario ₹1,575. It is a calculation from audited fundamentals, not an analyst target.
What is the Kwality Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at ₹1,211, about 71% lower versus a price of ₹4,195 (overvalued). Cautious scenario ₹848.01, optimistic scenario ₹1,575. The calculation is refreshed regularly with new filings.
What is the revenue of Kwality Pharmaceuticals Ltd (KPL)?
Kwality Pharmaceuticals Ltd reported trailing-twelve-month revenue of about ₹5.5B (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Kwality Pharmaceuticals Ltd (KPL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kwality Pharmaceuticals Ltd it is ₹1,211 per share (as of Nov 15, 2026), against a price of ₹4,195. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Kwality Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, KPL trades above its calculated fair value: price ₹4,195, fair value ₹1,211, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KPL?
No. The price is what the market pays today (₹4,195); the fair value is what the company's own numbers justify (₹1,211). For Kwality Pharmaceuticals Ltd the two are ₹2,984 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kwality Pharmaceuticals Ltd worth?
The market values Kwality Pharmaceuticals Ltd at about ₹43.5B (market capitalisation, as of Nov 15, 2026). Per share that is ₹4,195; our models calculate a fair value of ₹1,211 per share.
What do the bullish and bearish scenarios say about KPL?
Our models span a range for Kwality Pharmaceuticals Ltd: cautious scenario ₹848.01, base ₹1,211, optimistic ₹1,575 per share (as of Nov 15, 2026, price ₹4,195). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KPL?
Kwality Pharmaceuticals Ltd trades at a price-to-earnings ratio of 53.7 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,211 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 17.1. Other multiples: P/B 13.1, P/S 7.9, EV/EBITDA 31.9.
How solid is the balance sheet of Kwality Pharmaceuticals Ltd (KPL)?
Balance-sheet figures for Kwality Pharmaceuticals Ltd (as of Nov 15, 2026): return on equity 22.7%, debt of 0.09 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is KPL from its 52-week high?
Kwality Pharmaceuticals Ltd trades at ₹4,195, at its 52-week high of ₹4,195 and 381% above the low of ₹871.35 (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,211 is for.
Which stocks are comparable to Kwality Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kwality Pharmaceuticals Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price ₹4,195, calculated fair value ₹1,211 (−71%), Quality Score 57/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KPL calculated?
We run Kwality Pharmaceuticals Ltd through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹1,211 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Kwality Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kwality Pharmaceuticals Ltd (KPL)?
The closing price on Nov 18, 2026 was ₹4,195. Our model-based fair value is ₹1,211, about 71% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kwality Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case (₹1,575). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹848.01 to ₹1,575) leaves room in how you read the outcome.

Key figures of Kwality Pharmaceuticals Ltd

How large is the market capitalisation of Kwality Pharmaceuticals Ltd (KPL)?
The market capitalisation of Kwality Pharmaceuticals Ltd is ₹43.5B (≈ $466M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kwality Pharmaceuticals Ltd (KPL)?
The price-to-sales ratio of Kwality Pharmaceuticals Ltd is 7.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kwality Pharmaceuticals Ltd (KPL)?
Earnings per share at Kwality Pharmaceuticals Ltd are ₹78.10 (price ÷ EPS = P/E 53.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Kwality Pharmaceuticals Ltd (KPL)?
The net margin of Kwality Pharmaceuticals Ltd is 14.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kwality Pharmaceuticals Ltd (KPL)?
The return on equity (ROE) of Kwality Pharmaceuticals Ltd is 22.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kwality Pharmaceuticals Ltd (KPL)?
On an EBIT basis the return on assets of Kwality Pharmaceuticals Ltd is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kwality Pharmaceuticals Ltd (KPL)?
The operating margin of Kwality Pharmaceuticals Ltd is 22.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kwality Pharmaceuticals Ltd (KPL)?
Revenue at Kwality Pharmaceuticals Ltd is growing 45.6% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kwality Pharmaceuticals Ltd (KPL)?
Earnings per share at Kwality Pharmaceuticals Ltd are growing 115% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kwality Pharmaceuticals Ltd (KPL) generate?
The free cash flow of Kwality Pharmaceuticals Ltd is −₹324M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kwality Pharmaceuticals Ltd (KPL) carry?
The net debt of Kwality Pharmaceuticals Ltd is ₹1.3B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Kwality Pharmaceuticals Ltd in the live analysis

One click puts Kwality Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.